𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Regions of HIV reverse transcriptase involved in resistance to several nonnucleoside inhibitors : V.V. Sardana, E.A. Emini, L. Gotlib, D.J. Graham, D.W. Lineberger, W.J. Long, A.J. Schlabach, J.A. Wolfgang, and J.H. Condra. Department of Virus & Cell Biology, Merck Sharp & Dohme Research Laboratories, West Point, PA 19486.

Book ID
118392817
Publisher
Elsevier Science
Year
1992
Tongue
English
Weight
83 KB
Volume
17
Category
Article
ISSN
0166-3542

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

4 L-735, 524: An orally bioavailable hum
4 L-735, 524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor: E.A. Emini, J.P. Vacca, B.D. Dorsey, W.A. Schleif, R.B. Levin, S.L. McDaniel, P.L. Darke, J.A. Zugay, J.C. Quintero, O.M. Blahy, E. Roth, V.V. Sardana, A.J. Schlabach, J.H. Condra, L. Gotlib, K. Holloway, J. Lin, J.-W. Chen, D. Ostovic, P.S. Anderson and J.R. Huff. Merck Research Laboratories, West Point, PA 19486 USA. Bristol Myers Squibb Pharmaceutical Research Institute P.P. Box 4000, Princeton, New Jersey 08543 USA †5 Research Parkway Wallingford, Connecticut, 06492, USA
📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 62 KB
In vivo selection by monotherapy of HIV-
In vivo selection by monotherapy of HIV-1 variants resistant to multiple protease inhibitors: J.H. Condra, W.A. Schleif, O.M. Blahy, L.J. Gabryelski, D.J. Graham, J.C. Quintero, A. Rhodes, H.L. Robbins, E. Roth, M. Shivaprakash, D.L. Titus, T. Yang, H. Teppler†, K.E. Squirest††, P.J. Deutsch* and E.A. Emini. Departments of Antiviral Research and *Clinical Pharmacology, Merck Research Laboratories, West Point, PA 19486 USA; †Division of Infectious Diseases, Thomas Jefferson University, Philadelphia, PA 19107 USA, and ††Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 USA
📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 85 KB
94 Combination therapy with AZT prevents
94 Combination therapy with AZT prevents selection of HIV-1 variants that are highly resistant to the nonnucleoside reverse transcriptase inhibitor L-697, 661: E.A. Emini, S. Staszewski, C.L. Schneider, J.A. Waterbury, W.A. Schleif, R. Goehler, A. Deussen, S. Duerr, F.E. Massari, G.B. Calandra, B. Hoffstedt, and V.W. Byrnes; Merck Research Laboratories, West Point, PA, USA; Klinikum der Johann Wolfgang Goethe-Universitat, Frankfurt, Germany
📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 92 KB